Hoth Therapeutics (HOTH)
(Delayed Data from NSDQ)
$1.06 USD
-0.20 (-15.87%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $1.02 -0.04 (-3.77%) 7:58 PM ET
2-Buy of 5 2
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
HOTH 1.06 -0.20(-15.87%)
Will HOTH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HOTH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HOTH
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
HOTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for HOTH
Dow Tumbles 1%; US Crude Oil Stocks Fall
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
Hoth announces expansion of clinical sites for HT-001 Phase 2a trial
US Stocks Edge Higher; Jobless Claims Fall To 227,000
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001